In a year marked by macroeconomic uncertainty and renewed trade tensions that have shaken the equity market, CVS Health CVS has emerged as an unexpected outperformer. After a rough 2024, marked by ...

Investing.com — 美国联邦贸易委员会 (FTC)针对药房福利管理机构 (PBMs)有关胰岛素定价行为的诉讼即将恢复。此前，由于美国总统唐纳德·特朗普解雇了该机构的两名民主党委员，该案件曾暂时搁置。

The U.S. Federal Trade Commission’s lawsuit against major pharmacy benefit managers, including UnitedHealth Group’s Optum, CVS Health’s Caremark and Cigna’s Express Scripts, over insulin pricing ...

CVS Health is a BUY. Undervalued with growth potential, it outshines competitors despite sector challenges. See more on CVS ...

数据显示，2022年邮购和网上药店是美国消费者购买处方药的首选渠道，渠道收入最多，为1870.0亿美元。2022年美国医药电商企业中，Walgreens Boots Alliance和CVS health ...

Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...

Federal Trade Commission Chair Andrew Ferguson has reversed course on his decision to recuse himself from the agency's legal ...

A controversial lawsuit brought by the FTC against the largest PBMs over insulin pricing was delayed in part by Trump firings ...

"We can't survive another 12 months until the next session for them to try and pass it again," Spring City Pharmacy owner Brad Magg said about the state's bill.

CVS Health Corp. continues to fight a civil lawsuit that accuses the corporation and its retail pharmacists of wrongfully ...

The Federal Trade Commission put on hold a lawsuit against pharmacy-benefit manager (PBM) units of UnitedHealth, Cigna and ...

Employers, including Express Scripts parent company Cigna, seek to manage GLP-1 costs through programs administered by the ...